Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock price increase following the approval of its IPO registration by the China Securities Regulatory Commission (CSRC) [1] Group 1: IPO Details - BaiO Saite plans to raise 1.185 billion yuan through its IPO, with allocations of 454 million yuan for early drug development service platform construction, 316 million yuan for antibody drug research and evaluation, 165 million yuan for preclinical and clinical research, and 250 million yuan for working capital [1] Group 2: Strategic Partnerships - The company has recently announced collaborations with Germany's Tubulis and global technology leader Merck. Tubulis aims to utilize BaiO Saite's self-developed fully human antibodies to advance its ADC product development and commercialization, providing BaiO Saite with an upfront payment and potential milestone payments along with a share of net sales [1] - The partnership with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1]
百奥赛图-B盘中涨超12% 百奥赛图科创板IPO注册申请已获中国证监会同意